NTT-DOCOMO
NTT DOCOMO, INC. announced today that it will unveil a number of world-first technologies among a total of 31 innovative technologies for 5G Evolution, 6G, Generative AI and more during docomo Open House'24, an exhibition of cutting-edge technological advancements to be held in Tokyo on January 17 and 18.
A dedicated website (https://docomo-openhouse24.smktg.jp/public/application/add/32) will be accessible from January 17 until February 29 to showcase the exhibits, including highlights such as the following.
5G Evolution & 6G
Sub-terahertz bandwidth for ultra-high-capacity communication over 100Gbps
Cutting-edge technologies such as extreme-high-speed transmissions over 100Gbps, together with AI, will be deployed to meet the advanced requirements of 6G in the coming future. As one example, DOCOMO will launch new communication infrastructure to harness sub-terahertz bandwidths for the integration of physical space and cyberspace.
https://docomo-openhouse24.smktg.jp/public/session/view/97
FEEL TECH® for sharing sensory perceptions via human-augmentation platform
FEEL TECH® is the world's first technology for sharing taste sensations between individuals via DOCOMO's human-augmentation mobile platform. It is expected to be used in the metaverse, as well as in movies and animations, to incorporate taste expressions into extra-rich content that people will experience with an immersive sense of presence.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1221_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/76
Network technology for non-terrestrial areas, including air, sea and space
In the future, networks incorporating high-altitude platform stations (HAPS) will support disaster communications, ship and drone connectivity, and communications in mountainous and remote areas. The exhibit will showcase the latest technologies for non-terrestrial network (NTN) HAPS and underwater drones for mobile coverage beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1207_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/101
Next-generation cloud slicing and 5GC on AWS to meet specific network needs
Tailoring networks to meet specific quality-of-service requirements remains a challenge. This innovative solution combines end-to-end orchestration, QoS visualization and monitoring, and 5G Core from AWS to deliver flexible network quality for specific locations and time scenarios. By integrating the cloud, energy efficiency and on-demand network quality, the solution will help realize highly sustainable networks.
https://docomo-openhouse24.smktg.jp/public/session/view/69
5G application to address diverse mobile needs in industrial settings
The adoption of 5G in the industrial sector is still limited. More extensive 5G implementation in the industrial world will require comprehensive analysis and multi-dimensional verification that can address diverse mobile needs and environments. DOCOMO has developed an advanced yet portable simulator that makes it easy to visualize 5G wireless transmission characteristics and electromagnetic interference effects in each customer's unique industrial setting.
https://docomo-openhouse24.smktg.jp/public/session/view/107
Generative AI
Enlivening the metaverse with generative AI that creates non-player characters
The world-first technology from DOCOMO uses generative AI to create non-player characters in the metaverse. The innovative technology, which automatically generates each character's appearance, behavior and role to eliminate the need for experts with specialized know-how, will help realize more enriched metaverse experiences in the future.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_01.html
https://docomo-openhouse24.smktg.jp/public/session/view/67
DOCOMO will also showcase a selection of the above technologies at MWC Barcelona 2024 from February 26 to 29.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_00.html
Permission granted for the use of copyrighted images.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116271722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom